financetom
Market
financetom
/
Market
/
CNBC-TV18 Markets this week: Sensex, Nifty settle with marginal gains; Bharti Infratel, ICICI Bank top gainers
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CNBC-TV18 Markets this week: Sensex, Nifty settle with marginal gains; Bharti Infratel, ICICI Bank top gainers
Nov 8, 2019 9:23 AM

Indian equity markets ended the week with marginal gains on Friday, as benchmark indices shed gains after global rating agency Moody's revised the country's outlook to negative offsetting positive global cues.

Share Market Live

NSE

Trade sentiment turned cautious-to-negative as Moody's said the slowdown will be prolonged unless more concrete measures to boost rural spending and job creation are taken by the government.

The 30-share S&P BSE Sensex hit an intra-day record high for the third consecutive season at 40,749, but ended Friday's trade shedding over 330 points at 40,323. For the week, the Sensex added just 0.4 percent.

The Nifty was up 0.2 percent this week after the broader 50-share NSE frontline index settled below the 12,000-mark on Friday, at 11,908, losing almost 104 points. The index closed above the 12,000-mark on Thursday for the first time since June 4.

In broader markets, the Nifty MidCap index slipped almost a percent, while the Nifty Bank, the Metal and Realty indexes ended positive rising by up to 3.6 percent. The Nifty Auto, the PSU Bank and the FMCG slipped by up to 4.5 percent.

Bharti Infratel gained nearly 8 percent this week, leading among the Nifty stocks on large block deals after last week's bearish trends in the wake of Supreme Court judgement on the definition of the adjusted gross revenue of telecom companies.

ICICI Bank, Hindalco, Bajaj Finserv and JSW Steel were other major gainers this week, rising between 5 and 6 percent.

ICICI Bank gained nearly 6 percent this week after its second-quarter results as most brokerages remained bullish on the private banking major. Metal stocks benefited amid rising optimism on the US-China trade agreement.

Among top Nifty losers this week, Titan lost over 11 percent after the Tata Group company reported weaker-than-expected earnings for the quarter ended September. Investor sentiment was further dented with Titan Co reducing its jewellery sales growth guidance to 11-13 percent for the next two quarters from 20 percent earlier.

Zee Entertainment Enterprises (ZEEL) shares slipped overall more than 7 percent this week. The Essel Group company stock reduced losses towards the fag end of the week as Puneet Goenka was reappointed as managing director and chief executive officer for another period of five years.

Indian Oil, GAIL and UPL were other major losers this week along with Maruti Suzuki and Hindustan Unilever.

UPL's second quarter (July-September) consolidated net profit fell sharply by 67 percent due to one-time exceptional loss. The agrochemical company's profit during the quarter declined to Rs 89 crore, against Rs 270 crore reported in the same period last year. UPL reported a one-time loss of Rs 305 crore during the quarter against a loss of Rs 57 crore in corresponding quarter previous fiscal.

In the midcap space, Raymond shares surged over 36 percent this week as the company decides to demerge its lifestyle and fashion business and plans it to list separately. Every shareholder of Raymond Ltd will be issued the shares of the new company in the ratio of 1:1.

Raymond said the move will create a clear demarcation of lifestyle and other businesses, leading to the simplification of the group structure.

Max Finance, JB Chemicals, Indiabulls Housing Finance and DLF also gained between 9 and 19 percent this week. Realty shares gained after union finance minister Nirmala Sitharaman announced measures to boost the housing sector.

Cyient, Mahanagar Gas, TVS Motor, Godrej Agrovet and Greaves Cotton slipped between 3 and 4 percent this week.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sector Update: Consumer Stocks Edge Up in Afternoon Trading
Sector Update: Consumer Stocks Edge Up in Afternoon Trading
Sep 22, 2024
01:43 PM EDT, 09/18/2024 (MT Newswires) -- Consumer stocks rose Wednesday afternoon with the Consumer Staples Select Sector SPDR Fund (XLP) up 0.1% and the Consumer Discretionary Select Sector SPDR Fund (XLY) increasing 0.2%. In corporate news, General Mills' ( GIS ) fiscal Q3 results declined less than market expectations, while the Cheerios maker reiterated its full-year outlook. The shares...
US Equity Indexes Decline as Investors Await Fed's Policy Move, Guidance on Easing Path
US Equity Indexes Decline as Investors Await Fed's Policy Move, Guidance on Easing Path
Sep 22, 2024
12:15 PM EDT, 09/18/2024 (MT Newswires) -- US equity indexes fell in choppy midday trading Wednesday ahead of the Federal Reserve's policy announcement later in the afternoon. The S&P 500 index fell 0.2% to 5,624.3, with the Nasdaq Composite down 0.3% to 17,574.1 and the Dow Jones Industrial Average 0.1% lower at 41,551.5. Except for gains in consumer staples, energy,...
Top Midday Decliners
Top Midday Decliners
Sep 22, 2024
01:54 PM EDT, 09/18/2024 (MT Newswires) -- Cibus ( CBUS ) said Wednesday it priced an underwritten public offering of 3 million shares of its class A common stock at $4 apiece, targeting gross proceeds of about $12 million. Shares slumped 28% amid intraday trading volume at over 1.6 million compared with a daily average of about 177,000. Mullen Automotive...
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
Sep 22, 2024
Truist Securities has downgraded Incyte Corporation ( INCY ) , noting Jakafi’s (ruxolitinib) patent loss approaching in 2028. Jakafi is Incyte’s top-selling drug. It is indicated for polycythemia vera in adults, intermediate or high-risk myelofibrosis in adults, and steroid-refractory acute graft versus host disease in adult and pediatric patients. In second quarter 2024, the drug generated sales of $705.9 million, +3%...
Copyright 2023-2025 - www.financetom.com All Rights Reserved